Latest News about GILD
Recent news which mentions GILD
From Benzinga
Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday
December 31, 2024
From Benzinga
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
December 22, 2024
From Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
December 16, 2024
From Benzinga
From Benzinga
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
December 12, 2024
From Benzinga
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
December 09, 2024
From Benzinga
Looking At Gilead Sciences's Recent Unusual Options Activity
December 03, 2024
Tickers
GILD
From Benzinga
Price Over Earnings Overview: Gilead Sciences
November 25, 2024
From Benzinga
26 Analysts Assess Gilead Sciences: What You Need To Know
November 18, 2024
Tickers
GILD
From Benzinga
From Benzinga
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low
November 15, 2024
From Benzinga
3 Spectacular High-Yield Dividend Stocks to Buy in November
November 10, 2024
From Motley Fool
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
November 08, 2024
From Benzinga
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
November 07, 2024
From Benzinga
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
November 07, 2024
From Benzinga
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
November 06, 2024
Tickers
GILD
From Motley Fool
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
November 06, 2024
From Benzinga
From Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
October 24, 2024
From Motley Fool
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
October 21, 2024
From Benzinga
From Benzinga
From Benzinga
Evaluating Gilead Sciences: Insights From 15 Financial Analysts
October 21, 2024
Tickers
GILD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.